MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
RIGL stock logo

RIGL

Rigel Pharmaceuticals, Inc.

$27.53
0.03
 (0.11%)
[ms_data_label text=’Delayed data’]
Exchange:  NASDAQ
Market Cap:  508.564M
Shares Outstanding:  34786
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Raul R. Rodriguez
Full Time Employees:  162
Address: 
1180 Veterans Boulevard
South San Francisco
CA
94080
US
Website:  https://www.rigel.com
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/06 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue116,882179,278294,282
Gross Profit109,772160,631274,661
EBITDA-16,98128,512127,881
Operating Income-20,49124,192125,466
Net Income-25,09117,485367,024

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets117,225163,976513,594
Total Liabilities145,869160,688122,114
Total Stockholders Equity-28,6443,288391,480
Total Debt60,57959,96553,303
Cash and Cash Equivalents32,78656,74640,580

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-5,74331,47175,655
Capital Expenditure-15,000-360
Free Cash Flow-20,74331,43575,655
Net Income-25,09117,485367,024
Net Change in Cash8,32723,960-16,109

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)374,481.959Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)407,563.458Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)387,830.333Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-6,139.634Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-5,641.286Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-5,842.370Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)68,208.716Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)76,126.603Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)71,403.603Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)260,647.321Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)283,672.740Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)269,938.070Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)3.790Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)4.040Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)3.620Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)2Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)2Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
?Enterprise Value
 (TTM)
: 
  ?EV/FCF
 (TTM)
: 
?Dividend Yield
 (TTM)
: 
  ?Payout Ratio
 (TTM)
: 
?ROE
 (TTM)
: 
  ?ROIC
 (TTM)
: 
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
?P/B
 (TTM)
: 
  ?Current Ratio
 (TTM)
: 

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates RIGL intrinsic value between $26.15 – $99.96 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate RIGL Intrinsic Value

Common questions about RIGL valuation

Is RIGL (RIGL) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for RIGL (RIGL) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is RIGL a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether RIGL trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is RIGL’s P/E ratio?

You can see RIGL’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for RIGL?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is RIGL a good long-term investment?

Whether RIGL fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

RIGL

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

[ms_data_label text="Daily snapshot"]

0.11
MARKETSnap

Trading Metrics:

[ms_session_rows_unavailable]
Open: [ms_cell_or_dash table='trading_quote' column='open']   Previous Close: [ms_cell_or_dash table='trading_quote' column='previousClose']
Day Low: [ms_cell_or_dash table='trading_quote' column='dayLow']   Day High: [ms_cell_or_dash table='trading_quote' column='dayHigh']
Year Low:    Year High: 
Price Avg 50:    Price Avg 200: 
Volume:    Average Volume: 

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Is the Options Market Predicting a Spike in Rigel Pharmaceuticals Stock?
Rigel Pharmaceuticals Was Easy To Dismiss - Now It's Hard To Ignore (Rating Upgrade)
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2025 Earnings Call Transcript
Will Tavalisse Continue to Drive Rigel Pharmaceuticals' Growth in 2026?
FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside?
Rigel Pharmaceuticals, Inc. (RIGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read